Alamar Biosciences Successfully Lists on NASDAQ
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Should l Buy ALMR?
Source: Newsfilter
- Successful Listing: Alamar Biosciences successfully listed on NASDAQ on April 17, 2026, with an initial share price of $17 and an opening price of $22.6, achieving a market capitalization of approximately $1.5 billion, marking a significant milestone in the precision proteomics sector.
- Funding Background: Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to support the company through subsequent Series B and C rounds, holding approximately 19.2% of shares before the IPO, reflecting strong long-term confidence in the company's potential.
- Technological Innovation: Alamar's self-developed NULISA™ technology overcomes design limitations of existing proteomics tools, delivering ultra-high sensitivity and specificity in protein detection, filling critical gaps left by other methods, and paving the way for the future of early disease screening and precision diagnostics.
- Market Penetration: By the end of 2025, the ARGO™ HT system had over 100 units installed across 25 countries, serving more than 300 customers, indicating rapid growth in product market penetration and further solidifying Alamar's leadership position in the global proteomics market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALMR
Wall Street analysts forecast ALMR stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 17.000
Low
Averages
High
Current: 17.000
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alamar Biosciences Successfully Lists on NASDAQ
- Successful Listing: Alamar Biosciences successfully listed on NASDAQ on April 17, 2026, with an initial share price of $17 and an opening price of $22.6, achieving a market capitalization of approximately $1.5 billion, marking a significant milestone in the precision proteomics sector.
- Funding Background: Since 2020, Qiming Venture Partners has invested in multiple funding rounds, holding a 19.2% stake in Alamar, which underscores their confidence and support for the company's future growth trajectory.
- Technological Innovation: Alamar's proprietary NULISA™ technology overcomes design limitations of existing proteomics tools, offering ultra-high sensitivity and specificity to detect protein biomarkers at extremely low concentrations, filling a critical market gap and driving rapid product penetration.
- Market Impact: By the end of 2025, the ARGO™ HT system had over 100 units installed across 25 countries, serving more than 300 customers, which propels the company's rapid growth in precision diagnostics and early disease screening, indicating a transformative shift in healthcare technologies.
See More
Alamar Biosciences Successfully Lists on NASDAQ
- Successful Listing: Alamar Biosciences successfully listed on NASDAQ on April 17, 2026, with an initial share price of $17 and an opening price of $22.6, achieving a market capitalization of approximately $1.5 billion, marking a significant milestone in the precision proteomics sector.
- Funding Background: Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to support the company through subsequent Series B and C rounds, holding approximately 19.2% of shares before the IPO, reflecting strong long-term confidence in the company's potential.
- Technological Innovation: Alamar's self-developed NULISA™ technology overcomes design limitations of existing proteomics tools, delivering ultra-high sensitivity and specificity in protein detection, filling critical gaps left by other methods, and paving the way for the future of early disease screening and precision diagnostics.
- Market Penetration: By the end of 2025, the ARGO™ HT system had over 100 units installed across 25 countries, serving more than 300 customers, indicating rapid growth in product market penetration and further solidifying Alamar's leadership position in the global proteomics market.
See More
IPO Market Heats Up with $4.5 Billion Raised by Five Listings
- Record Fundraising: This week, five companies raised a total of $4.5 billion in IPOs, including two deals exceeding $1 billion, highlighting a significant uptick in market activity, particularly with Madison Air Solutions leading at $2.233 billion, reflecting strong demand for indoor air quality technologies.
- Strong Market Performance: Madison Air Solutions completed its IPO at the high end of pricing, achieving a market cap of $13.423 billion and a first-day return of 20%, indicating investor confidence in its air management technologies for data centers and commercial environments, which is expected to drive further market share growth.
- Biotech Breakthrough: Kailera Therapeutics raised $625 million, setting a record for US biotech IPOs with a market cap of $2.021 billion, as its lead candidate is currently in global Phase 3 trials, showcasing its potential in obesity treatment, with a first-day return of 63%.
- Growth in Defense Electronics: Arxis successfully raised $1.134 billion in its IPO, achieving a market cap of $11.633 billion; despite cyclical risks in aerospace and defense spending, its profitability and expanding free cash flow maintain its competitive edge, with a first-day return of 36%.
See More
Alamar Biosciences Shares Surge 40% After IPO Pricing
- Successful IPO Pricing: Alamar Biosciences priced its upsized IPO at $17 per share for approximately 11.3 million shares, aiming to raise around $191 million in gross proceeds, exceeding its initial target of $159 million, indicating strong market confidence in its business model.
- Impressive Stock Performance: The company's shares opened at $22.60, reflecting a 33% increase from the offering price, and closed at $23.65 around 1:20 PM ET, marking a ~40% jump and a market capitalization exceeding $1.6 billion, showcasing investor optimism about future growth.
- Significant Technological Edge: Alamar's NULISA technology, capable of detecting and quantifying over 100 protein biomarkers in a single biofluid sample, underpins its ARGO HT System, which is expected to enhance the company's competitiveness in the rapidly growing proteomics market.
- Strong Revenue Growth: In 2025, Alamar generated $74.2 million in revenue, achieving over 195% year-over-year growth, primarily driven by the successful rollout of the ARGO HT System, indicating effective market expansion and technology application.
See More
Alamar Biosciences Prices Upsized IPO at $17.00
- Successful IPO Pricing: Alamar Biosciences priced its upsized initial public offering at $17.00 per share for approximately 11.3 million shares, aiming to raise about $191 million in gross proceeds, reflecting strong market demand for its protein detection and analysis technologies.
- Trading Debut: The company is set to debut on the Nasdaq Global Select under the ticker symbol “ALMR” on Friday, marking a significant milestone in its commercial stage and laying the groundwork for future growth.
- Underwriter Option: Underwriters will have a 30-day option to purchase an additional ~1.7 million shares at the IPO price, providing the company with added financial flexibility and enhancing its capital structure.
- Adjusted Fundraising Goals: Earlier this week, Alamar aimed to offer ~9.4 million shares at a targeted price range of $15–$17, potentially raising up to $159 million at the top of the range, demonstrating the company's keen market insight and adaptability.
See More
Alamar Biosciences Raises $191 Million in IPO at High End of Range
- Significant Fundraising: Alamar Biosciences successfully raised $191 million by offering 11.3 million shares at $17 each, reaching the high end of its $15 to $17 range, indicating strong market demand for its protein biomarker detection platform.
- Oversubscription Success: The number of shares sold exceeded the original plan of 9.4 million by 20%, reflecting investor confidence in Alamar's proteomics technology, thereby strengthening the company's capital base to support future R&D.
- Technological Platform Advantage: Alamar's platform integrates proprietary instruments, consumables, and software to detect and analyze low-abundance protein biomarkers in biological samples, applicable across various fields from early-stage discovery to translational research, enhancing precision and consistency in disease detection.
- Clear Market Positioning: Based in Fremont, CA, the company plans to trade on Nasdaq under the symbol ALMR, and with this fundraising, Alamar aims to further solidify its market position in biomedical research and clinical applications.
See More
Alamar Biosciences Successfully Lists on NASDAQ
- Successful Listing: Alamar Biosciences successfully listed on NASDAQ on April 17, 2026, with an initial share price of $17 and an opening price of $22.6, achieving a market capitalization of approximately $1.5 billion, marking a significant milestone in the precision proteomics sector.
- Funding Background: Since 2020, Qiming Venture Partners has invested in multiple funding rounds, holding a 19.2% stake in Alamar, which underscores their confidence and support for the company's future growth trajectory.
- Technological Innovation: Alamar's proprietary NULISA™ technology overcomes design limitations of existing proteomics tools, offering ultra-high sensitivity and specificity to detect protein biomarkers at extremely low concentrations, filling a critical market gap and driving rapid product penetration.
- Market Impact: By the end of 2025, the ARGO™ HT system had over 100 units installed across 25 countries, serving more than 300 customers, which propels the company's rapid growth in precision diagnostics and early disease screening, indicating a transformative shift in healthcare technologies.
See More
Alamar Biosciences Successfully Lists on NASDAQ
- Successful Listing: Alamar Biosciences successfully listed on NASDAQ on April 17, 2026, with an initial share price of $17 and an opening price of $22.6, achieving a market capitalization of approximately $1.5 billion, marking a significant milestone in the precision proteomics sector.
- Funding Background: Qiming Venture Partners led Alamar's Series A financing in 2020 and continued to support the company through subsequent Series B and C rounds, holding approximately 19.2% of shares before the IPO, reflecting strong long-term confidence in the company's potential.
- Technological Innovation: Alamar's self-developed NULISA™ technology overcomes design limitations of existing proteomics tools, delivering ultra-high sensitivity and specificity in protein detection, filling critical gaps left by other methods, and paving the way for the future of early disease screening and precision diagnostics.
- Market Penetration: By the end of 2025, the ARGO™ HT system had over 100 units installed across 25 countries, serving more than 300 customers, indicating rapid growth in product market penetration and further solidifying Alamar's leadership position in the global proteomics market.
See More
IPO Market Heats Up with $4.5 Billion Raised by Five Listings
- Record Fundraising: This week, five companies raised a total of $4.5 billion in IPOs, including two deals exceeding $1 billion, highlighting a significant uptick in market activity, particularly with Madison Air Solutions leading at $2.233 billion, reflecting strong demand for indoor air quality technologies.
- Strong Market Performance: Madison Air Solutions completed its IPO at the high end of pricing, achieving a market cap of $13.423 billion and a first-day return of 20%, indicating investor confidence in its air management technologies for data centers and commercial environments, which is expected to drive further market share growth.
- Biotech Breakthrough: Kailera Therapeutics raised $625 million, setting a record for US biotech IPOs with a market cap of $2.021 billion, as its lead candidate is currently in global Phase 3 trials, showcasing its potential in obesity treatment, with a first-day return of 63%.
- Growth in Defense Electronics: Arxis successfully raised $1.134 billion in its IPO, achieving a market cap of $11.633 billion; despite cyclical risks in aerospace and defense spending, its profitability and expanding free cash flow maintain its competitive edge, with a first-day return of 36%.
See More
Alamar Biosciences Shares Surge 40% After IPO Pricing
- Successful IPO Pricing: Alamar Biosciences priced its upsized IPO at $17 per share for approximately 11.3 million shares, aiming to raise around $191 million in gross proceeds, exceeding its initial target of $159 million, indicating strong market confidence in its business model.
- Impressive Stock Performance: The company's shares opened at $22.60, reflecting a 33% increase from the offering price, and closed at $23.65 around 1:20 PM ET, marking a ~40% jump and a market capitalization exceeding $1.6 billion, showcasing investor optimism about future growth.
- Significant Technological Edge: Alamar's NULISA technology, capable of detecting and quantifying over 100 protein biomarkers in a single biofluid sample, underpins its ARGO HT System, which is expected to enhance the company's competitiveness in the rapidly growing proteomics market.
- Strong Revenue Growth: In 2025, Alamar generated $74.2 million in revenue, achieving over 195% year-over-year growth, primarily driven by the successful rollout of the ARGO HT System, indicating effective market expansion and technology application.
See More
Alamar Biosciences Prices Upsized IPO at $17.00
- Successful IPO Pricing: Alamar Biosciences priced its upsized initial public offering at $17.00 per share for approximately 11.3 million shares, aiming to raise about $191 million in gross proceeds, reflecting strong market demand for its protein detection and analysis technologies.
- Trading Debut: The company is set to debut on the Nasdaq Global Select under the ticker symbol “ALMR” on Friday, marking a significant milestone in its commercial stage and laying the groundwork for future growth.
- Underwriter Option: Underwriters will have a 30-day option to purchase an additional ~1.7 million shares at the IPO price, providing the company with added financial flexibility and enhancing its capital structure.
- Adjusted Fundraising Goals: Earlier this week, Alamar aimed to offer ~9.4 million shares at a targeted price range of $15–$17, potentially raising up to $159 million at the top of the range, demonstrating the company's keen market insight and adaptability.
See More
Alamar Biosciences Raises $191 Million in IPO at High End of Range
- Significant Fundraising: Alamar Biosciences successfully raised $191 million by offering 11.3 million shares at $17 each, reaching the high end of its $15 to $17 range, indicating strong market demand for its protein biomarker detection platform.
- Oversubscription Success: The number of shares sold exceeded the original plan of 9.4 million by 20%, reflecting investor confidence in Alamar's proteomics technology, thereby strengthening the company's capital base to support future R&D.
- Technological Platform Advantage: Alamar's platform integrates proprietary instruments, consumables, and software to detect and analyze low-abundance protein biomarkers in biological samples, applicable across various fields from early-stage discovery to translational research, enhancing precision and consistency in disease detection.
- Clear Market Positioning: Based in Fremont, CA, the company plans to trade on Nasdaq under the symbol ALMR, and with this fundraising, Alamar aims to further solidify its market position in biomedical research and clinical applications.
See More
